Clinical innovation in urology continues to move quickly as new diagnostics, therapies, and data-driven approaches reshape how clinicians understand and manage disease. At the same time, a familiar challenge remains: translating these advances into consistent, informed decision-making in everyday practice.

Real-world evidence (RWE) has the potential to help close this gap by reflecting how treatments perform across broader, more diverse patient populations than those typically included in clinical trials. But the challenge is not access to more data, it’s whether that data is usable, reproducible, and can be applied in a way that meaningfully informs clinical decisions and improves patient outcomes.

Getting from insight to impact requires more than access to information. It depends on whether real-world data is complete, reliable, and usable at the point of care.

The gap between data and decision-making

RWE offers a broader view of how treatments perform outside of clinical trials by reflecting what happens in routine care. Even so, its influence on day-to-day decision-making remains uneven.

Electronic health records, registries, and claims datasets contain valuable clinical detail, but they are often fragmented and inconsistently structured. A large share of clinically relevant information, often cited at around 80 percent, exists in unstructured formats such as physician notes, making it difficult to analyze at scale.

For many urologic conditions, even basic questions such as recurrence patterns or treatment sequencing are not consistently captured in a way that supports decision-making. Addressing this challenge requires a shift in focus from simply collecting data to making it usable.

Non-muscle invasive bladder cancer (NMIBC): turning data into direction

Non-muscle invasive bladder cancer, which represents the majority of newly diagnosed bladder cancer cases and affects a substantial patient population in the U.S., is a clear example of both the opportunity and the limitations of current RWE.

On paper, the treatment paradigm is well understood. In practice, it is highly variable. Patients move between Transurethral Resection of Bladder Tumor (TURBT), a minimally invasive surgical procedure used to diagnose, stage, and treat early-stage NMIBC, to intravesical therapies like Bacillus Calmette-Guérin (BCG), an intravesical immunotherapy used to treat early-stage NMIBC by stimulating the immune system to attack cancer cells, and surveillance in ways that are not consistently captured or standardized. Even clinically critical concepts, like BCG-unresponsive disease or recurrence, are often documented in narrative notes rather than structured fields, making them difficult to identify and track at scale.

What we’re starting to see in larger real-world datasets is a clearer picture of how care actually unfolds. For example, there is meaningful drop-off between BCG induction and maintenance in routine practice, and wide variation in how long patients remain on therapy before switching or discontinuing. Time to recurrence and progression also looks different outside of clinical trials, particularly in community settings where most patients are treated.

But the real unlock is not just observing these patterns—it’s defining them in a way that is consistent and reproducible. Once recurrence, progression, and treatment exposure are systematically captured and linked longitudinally, these datasets can start to answer more practical questions: when patients are most likely to recur, which treatment sequences are associated with better durability, and where care deviates from guidelines.

The next step is ensuring that these insights are integrated into guidelines and workflows so they can be used consistently in practice.

Prostate cancer diagnostics: from documentation to use

In prostate cancer, new diagnostics have the potential to improve early risk assessment and guide treatment decisions, but their real-world impact depends on how well the data is captured and used.

Today, key clinical inputs such as Prostate-Specific Antigen (PSA), a blood test used to screen for prostate cancer by measuring the amount of protein produced by the prostate, trends, imaging results, and biomarker findings are often recorded in semi-structured fields or embedded in narrative notes rather than standardized formats. This makes it difficult to evaluate how these tools are being used across broader patient populations or to consistently link them to downstream decisions.

Real-world analyses continue to show variation in treatment patterns and outcomes, reflecting both differences in clinical practice and inconsistencies in documentation. Until these data are captured in a more structured and longitudinal way, it remains challenging to assess whether new diagnostics are meaningfully changing patient management.

As data curation improves, there is a clear opportunity to move beyond documentation toward use where diagnostic information is not only captured, but systematically analyzed to understand its impact on care and outcomes.

From fragmented data to actionable evidence

These examples point to a broader issue. Having more data does not automatically lead to better decisions. The value of RWE depends on whether it can be translated into insights that clinicians can actually use.

Advances in data curation and artificial intelligence are helping move things in the right direction. Natural language processing, for example, is increasingly being used to extract structured variables from physician notes, helping convert previously inaccessible data into formats that can support analysis and decision-making.

At the same time, technology alone will not solve the problem. High-quality inputs, consistent documentation, and strong data governance are still essential. Clinician involvement is also key to ensuring that the data reflects real-world practice and can be trusted.

Making real-world evidence work for urology

The future of RWE in urology will depend less on how much data is available and more on how effectively it can be used. The field is moving toward more integrated, longitudinal datasets that capture the full patient journey, but the real value comes when that information supports decisions in real time.

This will require closer collaboration among clinicians, researchers, and technology partners, along with a shared focus on data quality and usability.

Ultimately, making RWE actionable means shortening the gap between insight and application. When data is reliable, complete, and easy to use, it can support better decisions, faster adoption of new therapies, and improved patient outcomes. In urology, that opportunity is well within reach.